Cost-Offsets of New Medications for Treatment of Schizophrenia
NBER Working Paper No. 12643
---- Acknowledgements ----
The authors gratefully acknowledge financial support from two NIMH grants, Economic Impacts of New Drugs (R01MH069721) and Modeling Treatment Use & Effectiveness in Mental Illness (R01MH061434). We are grateful to Richard Lindrooth for constructive comments on an earlier version of this paper. We also thank Christina Fu for expert programming assistance. An earlier version of this paper was presented at the NIMH 13th Biennial Conference on Economics and Mental Health. The views expressed herein are those of the author(s) and do not necessarily reflect the views of the National Bureau of Economic Research.